Herpes zoster epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
The incidence rate of herpes zoster ranges from 1.2 to 3.4 per 1,000 person-years among healthy individuals, increasing to 3.9–11.8 per 1,000 person‐years among those older than 65 years. <ref>Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845</ref> Similar incidence rates have been observed worldwide.<ref name="pmid17939895">{{cite journal| author=Araújo LQ, Macintyre CR, Vujacich C| title=Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America| journal=Herpes| volume=14| issue=Suppl 2| pages=40A–4A| year=2007| pmid=17939895| url=http://www.ihmf.org/journal/download/5%20-%20Herpes%2014.2%20suppl%20Araujo.pdf| format=PDF}}</ref> <ref>Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845</ref> Herpes zoster develops in an estimated 500,000 Americans each year.<ref name="pmid16050886">{{cite journal |author=Insinga RP |title=The incidence of herpes zoster in a United States administrative database |journal=J Gen Intern Med |volume=20 |issue=6 |pages=748–753 |year=2005 |pmid=16050886 |doi=10.1111/j.1525-1497.2005.0150.x |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16050886 }}</ref> Multiple studies and surveillance data demonstrate no consistent trends in incidence in the U.S. since the chickenpox vaccination program began in 1995.<ref>{{cite journal |journal= MMWR Recomm Rep |date=2007 |volume=56 |issue=RR-4 |pages=1–40 |title= Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP) |author= Marin M, Güris D, Chaves SS, Schmid S, Seward JF |pmid=17585291 |url=http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm}}</ref> It is likely that incidence rate will change in the future, due to the aging of the population, changes in therapy for malignant and autoimmune diseases, and changes in chickenpox vaccination rates; a wide adoption of zoster vaccination could dramatically reduce the incidence rate.<ref>Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845</ref> | The incidence rate of herpes zoster ranges from 1.2 to 3.4 per 1,000 person-years among healthy individuals, increasing to 3.9–11.8 per 1,000 person‐years among those older than 65 years. <ref>Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845</ref> Similar incidence rates have been observed worldwide.<ref name="pmid17939895">{{cite journal| author=Araújo LQ, Macintyre CR, Vujacich C| title=Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America| journal=Herpes| volume=14| issue=Suppl 2| pages=40A–4A| year=2007| pmid=17939895| url=http://www.ihmf.org/journal/download/5%20-%20Herpes%2014.2%20suppl%20Araujo.pdf| format=PDF}}</ref> <ref>Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845</ref> Herpes zoster develops in an estimated 500,000 Americans each year.<ref name="pmid16050886">{{cite journal |author=Insinga RP |title=The incidence of herpes zoster in a United States administrative database |journal=J Gen Intern Med |volume=20 |issue=6 |pages=748–753 |year=2005 |pmid=16050886 |doi=10.1111/j.1525-1497.2005.0150.x |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16050886 }}</ref> Multiple studies and surveillance data demonstrate no consistent trends in incidence in the U.S. since the chickenpox vaccination program began in 1995.<ref>{{cite journal |journal= MMWR Recomm Rep |date=2007 |volume=56 |issue=RR-4 |pages=1–40 |title= Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP) |author= Marin M, Güris D, Chaves SS, Schmid S, Seward JF |pmid=17585291 |url=http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm}}</ref> It is likely that incidence rate will change in the future, due to the aging of the population, changes in therapy for malignant and autoimmune diseases, and changes in chickenpox vaccination rates; a wide adoption of zoster vaccination could dramatically reduce the incidence rate.<ref>Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845</ref> In general, herpes zoster has no seasonal incidence and does not occur in epidemics.<ref>Thomas SL, Hall AJ (2004). "What does epidemiology tell us about risk factors for herpes zoster?". Lancet Infect Dis 4 (1): 26–33. doi:10.1016/S1473-3099(03)00857-0. PMID 14720565</ref> | ||
Most studies, but not all, suggest that the overall incidence of herpes zoster is increasing in the United States and elsewhere. This increase is independent of the effect of aging of the population. However, the rate of herpes zoster in U.S. children is declining. Children vaccinated against varicella appear to have a lower risk of reactivation of vaccine-strain VZV compared with reactivation of wild-type VZV. | Most studies, but not all, suggest that the overall incidence of herpes zoster is increasing in the United States and elsewhere. This increase is independent of the effect of aging of the population. However, the rate of herpes zoster in U.S. children is declining. Children vaccinated against varicella appear to have a lower risk of reactivation of vaccine-strain VZV compared with reactivation of wild-type VZV. | ||
| Line 17: | Line 17: | ||
===Prevalence=== | ===Prevalence=== | ||
Varicella zoster virus has a high level of [[infectivity]] and is prevalent worldwide,<ref>{{cite journal |author=Apisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P, Mundy LM |title=Outbreak of varicella-zoster virus infection among Thai healthcare workers |journal=Infect Control Hosp Epidemiol |volume=28 |issue=4 |pages=430-4 |year=2007 |pmid=17385149 |doi=10.1086/512639}}</ref> and has a very stable prevalence from generation to generation.<ref name="pmid11289797">{{cite journal |author=Abendroth A, Arvin AM |title=Immune evasion as a pathogenic mechanism of varicella zoster virus |journal=Semin. Immunol. |volume=13 |issue=1 |pages=27–39 |year=2001 |pmid=11289797 |doi=10.1006/smim.2001.0293}}</ref> VZV is a benign disease in a healthy child in developed countries. However, varicella can be lethal to individuals who are infected later in life or who have low immunity. The number of people in this high-risk group has increased, due to the HIV epidemic and the increase in immunosuppressive therapies. Infections of varicella in institutions such as hospitals are also a significant problem, especially in hospitals that care for these high-risk populations.<ref name="Weller">{{cite book|author=Weller TH|title=Varicella-herpes zoster virus. In: Viral Infections of Humans: Epidemiology and Control. Evans AS, Kaslow RA, eds.|publisher=Plenum Press|date=1997|pages=865-892|isbn=978-0306448553}}</ref> | Varicella zoster virus has a high level of [[infectivity]] and is prevalent worldwide,<ref>{{cite journal |author=Apisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P, Mundy LM |title=Outbreak of varicella-zoster virus infection among Thai healthcare workers |journal=Infect Control Hosp Epidemiol |volume=28 |issue=4 |pages=430-4 |year=2007 |pmid=17385149 |doi=10.1086/512639}}</ref> and has a very stable prevalence from generation to generation.<ref name="pmid11289797">{{cite journal |author=Abendroth A, Arvin AM |title=Immune evasion as a pathogenic mechanism of varicella zoster virus |journal=Semin. Immunol. |volume=13 |issue=1 |pages=27–39 |year=2001 |pmid=11289797 |doi=10.1006/smim.2001.0293}}</ref> VZV is a benign disease in a healthy child in developed countries. However, varicella can be lethal to individuals who are infected later in life or who have low immunity. The number of people in this high-risk group has increased, due to the HIV epidemic and the increase in immunosuppressive therapies. Infections of varicella in institutions such as hospitals are also a significant problem, especially in hospitals that care for these high-risk populations.<ref name="Weller">{{cite book|author=Weller TH|title=Varicella-herpes zoster virus. In: Viral Infections of Humans: Epidemiology and Control. Evans AS, Kaslow RA, eds.|publisher=Plenum Press|date=1997|pages=865-892|isbn=978-0306448553}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 27: | Line 22: | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Herpesviruses]] | [[Category:Herpesviruses]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 17:59, 18 September 2017
|
Herpes zoster Microchapters |
|
Diagnosis |
|---|
|
History and Symptoms |
|
Treatment |
|
Case Studies |
|
Herpes zoster epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Herpes zoster epidemiology and demographics |
|
Risk calculators and risk factors for Herpes zoster epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; L. Katie Morrison, MD; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Before introduction of varicella vaccine in the United States in 1995, varicella was endemic, with virtually all persons being infected by adulthood. Since implementation of the varicella vaccination program, incidence has declined in all age groups, with the greatest decline among children aged 1-4 years. Data from passive and active surveillance have indicated a decline in varicella cases of 70%-84% from 1995 through 2001 (1-3). The downward trend in varicella has continued in the United States through 2005 with an approximately 90% decline in incidence from 1995 in active surveillance sites with high vaccine coverage (CDC, unpublished data).
Epidemiology and Demographics
Incidence
The incidence rate of herpes zoster ranges from 1.2 to 3.4 per 1,000 person-years among healthy individuals, increasing to 3.9–11.8 per 1,000 person‐years among those older than 65 years. [1] Similar incidence rates have been observed worldwide.[2] [3] Herpes zoster develops in an estimated 500,000 Americans each year.[4] Multiple studies and surveillance data demonstrate no consistent trends in incidence in the U.S. since the chickenpox vaccination program began in 1995.[5] It is likely that incidence rate will change in the future, due to the aging of the population, changes in therapy for malignant and autoimmune diseases, and changes in chickenpox vaccination rates; a wide adoption of zoster vaccination could dramatically reduce the incidence rate.[6] In general, herpes zoster has no seasonal incidence and does not occur in epidemics.[7]
Most studies, but not all, suggest that the overall incidence of herpes zoster is increasing in the United States and elsewhere. This increase is independent of the effect of aging of the population. However, the rate of herpes zoster in U.S. children is declining. Children vaccinated against varicella appear to have a lower risk of reactivation of vaccine-strain VZV compared with reactivation of wild-type VZV.
Several studies report that the overall incidence of herpes zoster started increasing before the varicella vaccine was introduced in the United States. The reasons for this increase are not well understood. Currently, there is no consistent evidence that increases in herpes zoster incidence in the United States have been accelerated by the varicella vaccination program.
CDC continues to study the epidemiology of herpes zoster among adults and children and to monitor the effects of the U.S. varicella and zoster vaccination programs.
Prevalence
Varicella zoster virus has a high level of infectivity and is prevalent worldwide,[8] and has a very stable prevalence from generation to generation.[9] VZV is a benign disease in a healthy child in developed countries. However, varicella can be lethal to individuals who are infected later in life or who have low immunity. The number of people in this high-risk group has increased, due to the HIV epidemic and the increase in immunosuppressive therapies. Infections of varicella in institutions such as hospitals are also a significant problem, especially in hospitals that care for these high-risk populations.[10]
References
- ↑ Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845
- ↑ Araújo LQ, Macintyre CR, Vujacich C (2007). "Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America" (PDF). Herpes. 14 (Suppl 2): 40A–4A. PMID 17939895.
- ↑ Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845
- ↑ Insinga RP (2005). "The incidence of herpes zoster in a United States administrative database". J Gen Intern Med. 20 (6): 748–753. doi:10.1111/j.1525-1497.2005.0150.x. PMID 16050886.
- ↑ Marin M, Güris D, Chaves SS, Schmid S, Seward JF (2007). "Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 56 (RR-4): 1–40. PMID 17585291.
- ↑ Dworkin RH, Johnson RW, Breuer J et al. (2007). "Recommendations for the management of herpes zoster". Clin. Infect. Dis 44 Suppl 1: S1–26. doi:10.1086/510206. PMID 17143845
- ↑ Thomas SL, Hall AJ (2004). "What does epidemiology tell us about risk factors for herpes zoster?". Lancet Infect Dis 4 (1): 26–33. doi:10.1016/S1473-3099(03)00857-0. PMID 14720565
- ↑ Apisarnthanarak A, Kitphati R, Tawatsupha P, Thongphubeth K, Apisarnthanarak P, Mundy LM (2007). "Outbreak of varicella-zoster virus infection among Thai healthcare workers". Infect Control Hosp Epidemiol. 28 (4): 430–4. doi:10.1086/512639. PMID 17385149.
- ↑ Abendroth A, Arvin AM (2001). "Immune evasion as a pathogenic mechanism of varicella zoster virus". Semin. Immunol. 13 (1): 27–39. doi:10.1006/smim.2001.0293. PMID 11289797.
- ↑ Weller TH (1997). Varicella-herpes zoster virus. In: Viral Infections of Humans: Epidemiology and Control. Evans AS, Kaslow RA, eds. Plenum Press. pp. 865–892. ISBN 978-0306448553.